Subjects: Biology >> Biophysics submitted time 2016-05-12
Sun, Xianlei
Gao, Duo
Gao, Liquan
Zhang, Chenran
Yu, Xinhe
Jia, Bing
Wang, Fan
Liu, Zhaofei
Sun, Xianlei
Gao, Duo
Gao, Liquan
Zhang, Chenran
Yu, Xinhe
Jia, Bing
Wang, Fan
Liu, Zhaofei
Wang, Fan
Abstract： Significant evidence has indicated that tumor-associated macrophages (TAMs) play a critical role in the proliferation, invasion, angiogenesis, and metastasis of a variety of human carcinomas. In this study, we investigated whether near-infrared fluorescence (NIRF) imaging using a macrophage mannose receptor (MMR; CD206)-targeting agent could be used to noninvasively visualize and quantify changes in TAMs in vivo. The CD206-targeting NIRF agent, Dye-anti-CD206, was prepared and characterized in vitro and in vivo. By using NIRF imaging, we were able to noninvasively image tumor-infiltrating macrophages in the 4T1 mouse breast cancer model. Importantly, longitudinal NIRF imaging revealed the depletion of macrophages in response to zoledronic acid (ZA) treatment. However, ZA alone did not lead to the inhibition of 4T1 tumor growth. We therefore combined anti-macrophage ZA therapy and tumor cytotoxic docetaxel (DTX) therapy in the mouse model. The results demonstrated that this combination strategy could significantly inhibit tumor growth as well as tumor metastasis to the lungs. Based on these findings, we concluded that CD206-targeted molecular imaging can sensitively detect the dynamic changes in tumor-infiltrating macrophages, and that the combination of macrophage depletion and cytotoxic therapy is a promising strategy for the effective treatment of solid tumors.
Peer Review Status:
Awaiting Review
Subjects: Biology >> Biophysics >> Imaging Medicine and Biomedical Engineering submitted time 2016-05-11
Gao, Duo
Gao, Liquan
Zhang, Chenran
Liu, Hao
Jia, Bing
Wang, Fan
Liu, Zhaofei
Gao, Duo
Gao, Liquan
Zhang, Chenran
Liu, Hao
Jia, Bing
Wang, Fan
Liu, Zhaofei
Zhu, Zhaohui
Wang, Fan
Abstract： Integrin alpha v beta 6 is widely upregulated in variant malignant cancers but is undetectable in normal organs, making it a promising target for cancer diagnostic imaging and therapy. Using streptavidin-biotin chemistry, we synthesized an integrin alpha v beta 6-targeted near-infrared phthalocyanine dye-labeled agent, termed Dye-SA-B-HK, and investigated whether it could be used for cancer imaging, optical imaging-guided surgery, and phototherapy in pancreatic cancer mouse models. Dye-SA-B-HK specifically bound to integrin alpha v beta 6 in vitro and in vivo with high receptor binding affinity. Using small-animal optical imaging, we detected subcutaneous and orthotopic BxPC-3 human pancreatic cancer xenografts in vivo. Upon optical image-guidance, the orthotopically growing pancreatic cancer lesions could be successfully removed by surgery. Using light irradiation, Dye-SA-B-HK manifested remarkable antitumor effects both in vitro and in vivo. F-18-FDG positron emission tomography (PET) imaging and ex vivo fluorescence staining validated the observed decrease in proliferation of treated tumors by Dye-DA-B-HK phototherapy. Tissue microarray results revealed overexpression of integrin alpha v beta 6 in over 95% cases of human pancreatic cancer, indicating that theranostic application of Dye-DA-B-HK has clear translational potential. Overall, the results of this study demonstrated that integrin alpha v beta 6-specific Dye-SA-B-HK is a promising theranostic agent for the management of pancreatic cancer. (C) 2015 Elsevier Ltd. All rights reserved.
Peer Review Status:Awaiting Review
Subjects: Biology >> Biophysics submitted time 2016-05-11
Ma, Teng
Liu, Hao
Sun, Xianlei
Gao, Liquan
Shi, Jiyun
Zhao, Huiyun
Jia, Bing
Wan, Fan
Liu, Zhaofei
Ma, Teng
Liu, Hao
Sun, Xianlei
Gao, Liquan
Jia, Bing
Wan, Fan
Liu, Zhaofei
Shi, Jiyun
Zhao, Huiyun
Abstract： Cetuximab is an antiepidermal growth factor receptor (EGFR) monoclonal antibody that has received the approval of the Food and Drug Administration (FDA) for cancer treatment. However, most clinical studies indicate that cetuximab can only elicit positive effects on a subset of cancer patients. In this study, we investigated whether near-infrared fluorescence (NIRF) imaging of tumor vascular endothelial growth factor (VEGF) expression could be a biomarker for tumor early response to cetuximab therapy in preclinical wild-type and mutant tumor models of the KRAS gene. The treatment efficacy of cetuximab was determined in both HT-29 (wild-type KRAS) and HTC-116 (mutant KRAS) human colon cancer models. A VEGF-specific optical imaging probe (Dye755-Ran) was synthesized by conjugating ranibizumab (an anti-VEGF antibody Fab fragment) with a NIRF dye. Serial optical scans with Dye755-Ran were performed in HT-29 and HTC-116 xenograft models. By using longitudinal NIRF imaging, we were able to detect early tumor response on day 3 and day 5 after initiation of cetuximab treatment in the cetuximab-responsive HT-29 tumor model. Enzyme-linked immunosorbent assay (ELISA) confirmed that cetuximab treatment inhibited human VEGF expression in the KRAS wild-type HT-29 tumor but not in the KRAS mutant HCT-116 tumor. We have demonstrated that the antitumor effect of cetuximab can be noninvasively monitored by serial fluorescence imaging using Dye755-Ran. VEGF expression detected by optical imaging could serve as a sensitive biomarker for tumor early response to drugs that directly or indirectly act on VEGF.
Peer Review Status:Awaiting Review
Subjects: Biology >> Biophysics submitted time 2016-05-05
Li, Dan
Chen, Yuanyuan
Wang, Xia
Chen, Xin
Liu, Boli
Jia, Hongmei
Deuther-Conrad, Winnie
Steinbach, Joerg
Brust, Peter
Jia, Bing
Dong, Chengyan
Abstract： We have designed and synthesized a series of cyclopentadienyl tricarbonyl rhenium complexes containing a 5,6-dimethoxyisoindoline or a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline pharmacophore as sigma(2) receptor ligands. Rhenium compound 20a possessed low nanomolar sigma(2) receptor affinity (K-i = 2.97 nM) and moderate subtype selectivity (10-fold). Moreover, it showed high selectivity toward vesicular acetylcholine transporter (2374-fold), dopamine D-2L receptor, NMDA receptor, opiate receptor, dopamine transporter, norepinephrine transporter, and serotonin transporter. Its corresponding radiotracer [Tc-99m]20b showed high uptake in a time- and dose-dependent manner in DU145 prostate cells and C6 glioma cells. In addition, this tracer exhibited high tumor uptake (5.92% ID/g at 240 min) and high tumor/blood and tumor/muscle ratios (21 and 16 at 240 min, respectively) as well as specific binding to sigma receptors in nude mice bearing C6 glioma xenografts. Small animal SPECT/CT imaging of [Tc-99m]20b in the C6 glioma xenograft model demonstrated a clear visualization of the tumor at 180 min after injection.
Peer Review Status:Awaiting Review
Subjects: Biology >> Biophysics submitted time 2016-05-05
Dong, Chengyan
Yang, Sujuan
Zhao, Huiyun
Liu, Zhaofei
Jia, Bing
Wang, Fan
Dong, Chengyan
Yang, Sujuan
Zhao, Huiyun
Liu, Zhaofei
Jia, Bing
Wang, Fan
Dong, Chengyan
Shi, Jiyun
Wang, Fan
Zhao, Huiyun
Zhong, Lijun
Wang, Fan
Abstract： We describe herein dual-modality imaging of intraperitoneal colon tumor using an avidin/biotin pretargeting system. A novel dual-modality probe,Tc-99m-HYNIC-lys(Cy5.5)-PEG4-biotin,was designed, synthesized and characterized. Single-photon emission computed tomography/computed tomography (SPECT/CT) imaging and near infrared fluorescence (NIRF) imaging were developed using intraperitoneal LS180 human colon adenocarcinoma xenografts. Following avidin preinjection for 4 hours, 99mTc-HYNIC-lys(Cy5.5)-PEG4-biotin could successfully detect colon tumors of different sizes inside the abdominal region using both modalities, and the imaging results showed no differences. Biodistribution studies demonstrated that the tumors had a very high uptake of the probe (TcHYNIC)-Tc-99m-lys(Cy5.5)-PEG4-biotin(12.74 +/- 1.89% ID/g at 2 h p.i.), and the clearance from blood and other normal tissues occured very fast. The low tumor uptake in the non-pretargeted mice (1.63 +/- 0.50% ID/g at 2 h p.i.) and tumor cell staining results showed excellent tumor binding specificity of the pretargeting system. The ability of the novel probe to show excellent imaging quality with high tumor-to-background contrast, a high degree of binding specificity with tumors and excellent in vivo biodistribution pharmacokinetics should prove that the avidin/biotin based dual-modality pretargeting probe is a promising imaging tool during the entire period of tumor diagnosis and treatment.
Peer Review Status:Awaiting Review
Subjects: Biology >> Biophysics >> Imaging Medicine and Biomedical Engineering submitted time 2016-05-05
Zhang, Chenran
Gao, Liquan
Liu, Hao
Gao, Duo
Lai, Jianhao
Jia, Bing
Wang, Fan
Liu, Zhaofei
Zhang, Chenran
Gao, Liquan
Liu, Hao
Gao, Duo
Lai, Jianhao
Jia, Bing
Wang, Fan
Liu, Zhaofei
Cai, Yuehong
Wang, Fan
Abstract： Tumor-associated macrophages (TAMs) play essential roles in tumor invasion and metastasis, and contribute to drug resistance. Clinical evidence suggests that TAM levels are correlated with local tumor relapse, distant metastasis, and poor prognosis in patients. In this study, we synthesized a TAM-targeted probe (IRD-alpha CD206) by conjugating a monoclonal anti-CD206 antibody with a near-infrared phthalocyanine dye. We then investigated the potential application of the IRD-alpha CD206 probe to near-infrared fluorescence (NIRF) imaging and photoimmunotherapy (PIT) of tumors resistant to treatment with the kinase inhibitor sorafenib. Sorafenib treatment had no effect on tumor growth in a 4T1 mouse model of breast cancer, but induced M2 macrophage polarization in tumors. M2 macrophage recruitment by sorafenib-treated 4T1 tumors was noninvasively visualized by in vivo NIRF imaging of IRD-alpha CD206. Small-animal single-photon emission computed tomography (SPECT)/CT and intratumoral micro distribution analysis indicated TAM-specific localization of the IRD-alpha CD206 probe in 4T1 tumors after several rounds of sorafenib treatment. Upon light irradiation, IRD-alpha CD206 suppressed the growth of sorafenib-resistant tumors. In vivo CT imaging and ex vivo histological analysis confirmed the inhibition of lung metastasis in mice by IRD-alpha CD206 PIT. These results demonstrate the utility of the IRD-alpha CD206 probe for TAM-targeted diagnostic imaging and treatment of tumors that are resistant to conventional therapeutics. (C) 2016 Elsevier Ltd. All rights reserved.
Peer Review Status:Awaiting Review
Hits
Hits
Downloads
Comment